Search results

Sjogrens hypergammaglobulinemia correlates with disease activity, severity and some extraglandular manifestations. It seems to be reported to be common in Sjogrens but when i look younger patients with dysautonomia/MECFS/SFN etc dominant symptoms it is extremely rare to get to the stage of...

I thought Sjogren's especially is known for hypergammaglobulinemia. With early Sjogrens, presenting as dysautonomia, the levels of IgG can show rising trend, but still within limits. I don't know if there is a study on this, but seems to take a long time for Sjogrens to progress enough to have a...

What's new? One SLE patient who got Cabaletta CD19 for lupus nephritis had a severe, grade 4 neurotoxicity (ICANS). It says she recovered after treatment and the study continues. Still scary, huh?! other than this: for those who have small fiber neuropathy (SFN), and even better if you have...

I mentioned allogeneic CAR-T case reports (BRLmed a company who have also BCMA in the pipeline) in scleroderma and myositis. The part I especially like: https://www.shine.cn/news/metro/2407169316/

not really. Nothing for Sjogrens, nothing for POTS/SFN which should have a separate trial like with Vyvgart, hope someone from BCMA/BAFF only trials recognizes this. there is an upcoming RA trial: Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With...

and now almost nobody wants rituximab, so easy to get it . Will it take 25 years so nobody wants CAR-T so I can finally access it? :laugh:

and this especially: First case report from China with donor (allogeneic) off the shelf CAR-T cells lower chemo dose used her disease activity score - SLEDAI went from 18 to 0 After a series of rigorous examinations and evaluations, Li Ting was selected to participate in the clinical trial. The...

This one is also interesting : A woman successfully became pregnant and gave birth to a daughter after CAR-T treatment for SLE "Thanks to the advanced technology of the Municipal People's Hospital, becoming a mother successfully is the happiest thing for our whole family." On May 27, Xiao Du...

Pretty sure I found a study years ago where 60-70% of CIDP had SFN too, and that the same drugs are used (found effective?) like IVIG, cyclophosphamide, Vyvgart (?) and both SFN and/or CIDP co-occur with Sjogrens... , I'll keep my hope.

BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy hope this means for SFN too CAR T-Cell Therapy Seems Safe and Effective in CIDP A new case report of bi-specific CAR T-cell therapy targeting BCMA and CD19 for treating chronic inflammatory...

Exploring the clinical and immunopathological association between Long COVID and Sjögren's Disease in mice and humans Sponsored by: Olink Proteomics +25pts SPEAKER Cuong Nguyen, PhD Associate Professor, University of Florida BIOGRAPHY EVENT DATE & TIME Date: May 30, 2024 Time: 9:00 AM...

I guess, he might mean that because I cant really wait and be untreated for 5 years, I should at least see 6 months data, to see I am not getting a really weak product that wont keep several years of remission (he was saying in a sense to buy myself few years and then repeat it if needed when...

Dual cd19-bcma SLE researcher, from icellgene, told me to ask 6 months data when doing it...to be sure it's a reset...I guess whoever relapsed for now was within 6 months. He was seeing significant number of relapses w only CD19. He is very against it. But I wonder, for more less isolated LN...

Well IASO Bio also has such graphs with even more clear IgG to near 0, with only BCMA. But in their recent paper they mentioned something like "the persistence of CAR-T cells in autoimmune patients should be improved to keep an ongoing remission" That got me thinking if someone relapsed from...

Hmm IgG went to "0" very fast so seems it can't be late plasma cells dying?! Most patients were on 5g IVIG

From the recent report with dual BCMA CD19 Why would anti-SSA persist until 100+ days and then rapidly fall, what would be the explanation for this, if dual deleted every plasma cell, @Jonathan Edwards?

A study with dual CD19-BCMA CAR-T, for 13 SLE patients is published, with up to 46 months of follow-up. All patients are in remission besides P11 who received half of the dose (see the quote below) It seems they have used much less chemotherapy,they mention only 300mg/m2, cyclophosphamide, and...

Yes, so in any case it is not likely because as the authors stated because of CAR-T cells persistence or prolonged nycophenolate?!

@Jonathan Edwards so do you think that the persistence of CAR-T cells for 11 months (vs. average 3) is responsible for the complete disappearance of anti-scl70 in this case, or it was more just a natural death of plasmablasts, not happening all at once? From the case report: interesting that...